Conference Coverage
Conference Coverage
Cognitive behavioral therapy app lowers A1c in type 2 diabetes
People with type 2 diabetes who used a smartphone app for cognitive behavioral therapy had a significant drop in their A1c levels.
Conference Coverage
Statins boost glycemia slightly, but CVD benefits prevail
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.
Conference Coverage
If a saphenous graft is available, treat limb threatening ischemia surgically
Surgery beats endovascular treatment for limb threatening ischemia when saphenous grafts are an option, according to the BEST-CLI trial.
Conference Coverage
NAFLD patients with diabetes have higher fibrosis progression rate
Patients with type 2 diabetes had about a 2-year faster progression to fibrosis.
Conference Coverage
Triglyceride-lowering fails to show CV benefit in large fibrate trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on...
Conference Coverage
Drug repurposing ‘fast track’ to new medicines for obesity, diabetes
“We would like to progress some of these compounds to preclinical and clinical trials, but need to raise the funds for this expensive research.”...
Conference Coverage
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.
Conference Coverage
Dapagliflozin DELIVERs regardless of systolic pressure in HFpEF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with heart failure might present a...